On Thursday, Immatics N.V. (NASDAQ:IMTX) stock is trading lower after the company commenced an underwritten public offering ...

(RTTNews) - Immatics N.V. (IMTX) Thursday reported updated data from the Phase 1b study of its ACTengine cell therapy IMA203 in melanoma patients. ACTengine is a personalized therapy in which a ...

Immatics has vaulted into phase 3 on the strength of early-stage data. The biotech is gearing up to start a pivotal trial of ...

Tempest Therapeutics enters a Phase 3 trial for its liver cancer drug amezalpat, in collaboration with Roche. The trial ...

A phase 1b trial showed promising results among patients with relapsed or refractory chronic lymphocytic leukemia.

The company is preparing for the Phase 3 study start in the first quarter of 2025BRISBANE, Calif., Oct. 10, 2024 (GLOBE ...

Danish biotech Zealand Pharma is targeting the “next generation” of weight loss drugs as competitors pile into a market ...

The Union Cabinet on Wednesday (October 9, 2024) approved the development of the National Maritime Heritage Complex (NMHC) at ...

The drug is expected to offer nerve regeneration, potentially modifying the disease in diabetic peripheral neuropathy ...

Post hoc analysis of Phase 1b/2a study demonstrated statistically significant difference in time-to-first-relapse for ...

Analyst Naz Rahman of Maxim Group reiterated a Buy rating on Viking Therapeutics (VKTX – Research Report), retaining the price target of ...

India is grappling with a substantial burden of diabetes-related complications with diabetic peripheral neuropathy being a ...